Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBT: 2009-2024

Historic EBT for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $167.1 million.

  • Ironwood Pharmaceuticals' EBT rose 291.62% to $68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.5 million, marking a year-over-year increase of 226.13%. This contributed to the annual value of $167.1 million for FY2024, which is 114.23% up from last year.
  • Ironwood Pharmaceuticals' EBT amounted to $167.1 million in FY2024, which was up 114.23% from -$1.2 billion recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' EBT registered a high of $252.4 million during FY2022, and its lowest value of -$1.2 billion during FY2023.
  • In the last 3 years, Ironwood Pharmaceuticals' EBT had a median value of $167.1 million in 2024 and averaged -$251.7 million.
  • In the last 5 years, Ironwood Pharmaceuticals' EBT slumped by 565.33% in 2023 and then skyrocketed by 114.23% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' EBT (Yearly) stood at $108.9 million in 2020, then surged by 84.32% to $200.7 million in 2021, then increased by 25.80% to $252.4 million in 2022, then tumbled by 565.33% to -$1.2 billion in 2023, then soared by 114.23% to $167.1 million in 2024.